Mersana Therapeutics Inc (NASDAQ:MRSN) saw an upside of 0.79% to close Friday at $1.27 after adding $0.01 on the day. The 5-day average trading volume is 1,398,880 shares of the company’s common stock. It has gained $1.4800 in the past week and touched a new high 1 time within the past 5 days. An average of 2,643,315 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 7,830,478.
MRSN’s 1-month performance is 4.96% or $0.0400 on its low of $1.1100 reached on 08/31/23. The company’s shares have touched a 52-week low of $0.80 and high of $9.62, with the stock’s rally to the 52-week high happening on 06/12/23. YTD, MRSN has lost -78.33% or -$4.5900 and has reached a new high 20 times. However, the current price is down -86.80% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
MRSN stock investors last saw insider trading activity on Aug 17.MISRA TUSHAR (SVP, Chief Manuf. Officer) most recently sold 1,908 shares at $1.18 per share on Aug 17. This transaction cost the insider $2,251. SVP, Chief Legal Officer, Carvajal Alejandra, sold 3,944 shares at a price of $3.89 on Apr 27. Then, on Jan 17, President & CEO Protopapas Anna sold 17,346 shares at a price of $5.74 per share. This transaction amounted to $99,566.
Valuation Metrics
MRSN stock has a beta of 1.38. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 3.95 while the price-to-book (PB) in the most recent quarter is 1.70.
Mersana Therapeutics Inc’s quick ratio for the period ended June 29 was 3.97, with the current ratio over the same period at 3.97. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.36, while the total debt to equity was 0.39. In terms of profitability, the gross margin trailing 12 months is 97.06%. The trailing 12-month EBITDA margin is -763.10% while for the period ending June 29, Mersana Therapeutics Inc’s operating margin was -567.62%. The firm’s gross profit as reported stood at $230.35 million against revenue of $26.58 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 3.85% to -$54.31 million, while revenue of -$56.16 million was -3.41% off the previous quarter. Analysts expected MRSN to announce -$0.44 per share in earnings in its latest quarter, but it posted -$0.47, representing a -6.80% surprise. EBITDA for the quarter stood at more than -$57.96 million. MRSN stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 221.2 million, with total debt at $35.11 million. Shareholders hold equity totaling $120.51 million.
Let’s look briefly at Mersana Therapeutics Inc (MRSN) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 22 September was 42.67% to suggest the stock is trending Neutral, with historical volatility in this time period at 65.89%.
The stock’s 5-day moving average is $1.3140, reflecting a -10.56% or -$0.1500 change from its current price. MRSN is currently trading +3.25% above its 20-day SMA, -73.04% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -65.58% and SMA200 by-81.99%.
Stochastic %K and %D was 39.11% and 48.76% and the average true range (ATR) pointed at 0.1043. The RSI (14) points at 40.25%, while the 14-day stochastic is at 39.47% with the period’s ATR at 0.1232. The stock’s 9-day MACD Oscillator is pointing at -0.0911 and -0.0562 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Mersana Therapeutics Inc (NASDAQ: MRSN), Robert W. Baird downgraded it to a Neutral rating. They previously had an Outperform rating on the stock. Analysts offering their rating for MRSN stock have a consensus rating for the stock as Hold. Currently, 1 brokerage advisors rate MRSN as a “sell,”, while 6 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 2 have offered a “buy” rating.
What is MRSN’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $1.00 and a high of $4.00, with their median price target at $1.50. Looking at these predictions, the average price target given by analysts is for Mersana Therapeutics Inc (MRSN) stock is $2.00.
